Table 2.
Baseline characteristics of heparin versus. standard ATT group in the matched population
| Baseline variable |
Early IVH group (n = 117) |
Standard ATT group (n = 234) |
P value |
|---|---|---|---|
| Age, mean (SD), year | 61 (9) | 60 (12) | 0.81 |
| Male sex | 83 (70.3) | 171 (73.1) | 0.67 |
| Hypertension | 71 (60.7) | 142 (60.7) | 1.00 |
| Diabetes mellitus | 18 (15.4) | 36 (15.4) | 1.00 |
| Atrial fibrillation | 14 (12.0) | 27 (11.5) | 0.91 |
| Prior stroke | 32 (27.4) | 64 (27.4) | 1.00 |
| Prestroke mRS score > 1 | 4 (3.4) | 11 (4.7) | 0.78 |
| Cigarette smoking | 48 (41.0) | 99 (42.3) | 0.82 |
| Systolic blood pressure, mean (SD), mmHg | 155 (23) | 155 (21) | 0.91 |
| Admission NIHSS score, median (IQR) | 14 (10–18) | 14 (8–20) | 0.49 |
| Onset‐to‐needle time, median (IQR), hour | 4.0 (3.0–4.8) | 4.0 (2.5–4.9) | 0.85 |
| Full dose of tPA | 69 (59.0) | 142 (60.7) | 0.76 |
| Stroke territory | 1.00 | ||
| Anterior circulation | 67 (57.3) | 134 (57.3) | |
| Posterior circulation | 50 (42.7) | 100 (42.7) | |
| Stroke subtype by TOAST criteria | 0.57 | ||
| Large artery atherosclerosis | 68 (58.1) | 154 (65.8) | |
| Small artery occlusion | 19 (16.2) | 30 (12.8) | |
| Cardioembolism | 15 (12.8) | 25 (10.7) | |
| Other determined or undetermined etiology | 15 (12.8) | 25 (10.7) |
Values are numbers with percentages in parentheses, unless indicated otherwise.
Abbreviations: ATT, antithrombotic therapy, IQR, interquartile range, IVH, intravenous heparin, mRS, modified Rankin Scale, NIHSS, National Institutes of Health Stroke Scale, SD, standard deviation, TOAST, Trial of Org 10,172 in Acute Stroke Treatment, tPA, tissue Plasminogen Activator.